Journal of Cancer Research and Clinical Oncology

, Volume 128, Issue 8, pp 433–442

Augmented antitumour effects of combination therapy with TNP-470 and chemoimmunotherapy in mice

  • Anna Dabrowska-Iwanicka
  • Dominika Olszewska
  • Ahmad Jalili
  • Marcin Makowski
  • Tomasz Grzela
  • Maria Marczak
  • Grazyna Hoser
  • Adam Giermasz
  • Jakub Golab
  • Marek Jakóbisiak
Original Paper

DOI: 10.1007/s00432-002-0356-z

Cite this article as:
Dabrowska-Iwanicka, A., Olszewska, D., Jalili, A. et al. J Cancer Res Clin Oncol (2002) 128: 433. doi:10.1007/s00432-002-0356-z

Abstract

Purpose. To investigate antitumour efficacy of the combination of the antiangiogenic agent TNP-470 combined with chemoimmunotherapy in different tumour models in mice

Materials. B6D2F1 mice and BALB/c mice were inoculated in the footpad of the right hind limb with B16F10 melanoma cells or colon adenocarcinoma cells C-26, respectively. Subsequently, they received therapy consisting of TNP-470 and/or IL-12 and tumour growth was observed. In the melanoma model this therapy regimen was combined with cisplatin in a subtherapeutic dose. The antiangiogenic action of the tested agents was evaluated using tumour-induced angiogenesis assay in vivo. In order to analyse interactions between TNP-470 (or cisplatin) and IFN-γ on tumour cells in vitro, the following methods were used: MTT assay, Western blot analysis, and flow cytometry analysis.

Results. Administration of the combined therapy with TNP-470 and IL-12 resulted in augmented antitumour activity in colon-26 and B16F10 melanoma models. Addition of cisplatin further enhanced efficacy of this combined therapy in the melanoma model. We showed that antitumour activity of this combined therapy is mediated by multiple mechanisms: not only is enhancement of the antiangiogenic activity mediated by TNP-470 and IL-12 but also by the synergistic cytostatic/cytotoxic action of IL-12-induced IFN-γ and TNP-470 or cisplatin on tumour cells. The experiments revealed that TNP-470 together with IFN-γ leads to the increased expression of p21 protein in cancer cells, which in turn may contribute to their cytostatic/cytotoxic action in vitro.

Conclusion. Our experiments show a successful TNP-470-based combination therapy and suggest that the enhancement of the antitumour activity could be explained by a concomitant effect on both endothelial and tumour cell compartments.

Melanoma Tumour therapy Antiangiogenic agents TNP-470 IL-12 Mice

Copyright information

© Springer-Verlag 2002

Authors and Affiliations

  • Anna Dabrowska-Iwanicka
    • 1
  • Dominika Olszewska
    • 1
  • Ahmad Jalili
    • 1
  • Marcin Makowski
    • 1
  • Tomasz Grzela
    • 3
  • Maria Marczak
    • 4
  • Grazyna Hoser
    • 5
  • Adam Giermasz
    • 1
  • Jakub Golab
    • 1
  • Marek Jakóbisiak
    • 1
  1. 1.Department of Immunology, Center of Biostructure, Medical University of Warsaw, Chalubińskiego 5, 02–004 Warsaw, Poland
  2. 2.Department of Lymphoproliferative Diseases, Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology, Roentgena 5, 02–781 Warsaw, Poland
  3. 3.Department of Histology and Embryology, Center of Biostructure, Medical University of Warsaw, Warsaw, Poland
  4. 4.Department of Dermatology, Medical University of Warsaw, Koszykowa 82A, 02–008 Warsaw, Poland
  5. 5.Department of Clinical Cytology, Medical Center of Postgraduate Education, Marymoncka 99, Warsaw, Poland